Aarey Drugs & Pharmaceuticals Ltd.

Aarey Drugs & Pharmaceuticals Ltd.

105.57
INR
-5.55
(-4.99%)
1.47EPS
61.37P/E
2.57BMarket Cap

Total Valuation

INR

As of June 30, 2026, Aarey Drugs & Pharmaceuticals Ltd. carries a market capitalization of 2.57B, placing it among publicly traded companies globally. Its enterprise value stands at 2.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.57B
Enterprise Value2.57B

Share Statistics

As of June 30, 2026, Aarey Drugs & Pharmaceuticals Ltd. has 28.45M shares outstanding.

Shares Outstanding28.45M

Valuation Ratios

As of June 30, 2026, Aarey Drugs & Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 61.37.

PE Ratio61.37
PS Ratio0.62

Enterprise Valuation

As of June 30, 2026, Aarey Drugs & Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 37.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 71.66 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.57B versus a market cap of 2.57B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.62
EV / EBITDA37.76
EV / EBIT71.66

Financial Position

These figures are as of June 30, 2026.

Interest Coverage1.21

Taxes

INR

Over the twelve months ended June 30, 2026, Aarey Drugs & Pharmaceuticals Ltd. recorded 270,000.00 in income tax expense. That works out to an effective tax rate of 0.64, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 42.01M, leaving 41.74M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax270,000.00
Effective Tax Rate0.64

Stock Price Statistics

INR

As of the close on November 17, 2026, Aarey Drugs & Pharmaceuticals Ltd.'s stock has gained approximately 8.84% over the past 52 weeks. The 50-day moving average sits at 105.20, while the 200-day moving average is 84.80.

52-Week Price Change8.84%
50-Day Moving Average105.20
200-Day Moving Average84.80

Income Statement

INR

Over the twelve months ended June 30, 2026, Aarey Drugs & Pharmaceuticals Ltd. generated 4.15B in revenue and converted that into 41.74M in net income, yielding earnings per share of 1.47. EBITDA reached 67.95M, while operating income came in at 35.80M.

Revenue4.15B
Gross Profit158.61M
Operating Income35.80M
Pretax Income42.01M
Net Income41.74M
EBITDA67.95M
EBIT35.80M
Earnings Per Share (EPS)1.47

Margins

Over the twelve months ended June 30, 2026, Aarey Drugs & Pharmaceuticals Ltd. posted a gross margin of 3.82, reflecting its pricing power and cost economics. The operating margin of 0.86 and net profit margin of 1.01 provide insight into operational efficiency.

Gross Margin3.82
Operating Margin0.86
Pretax Margin1.01
Profit Margin1.01
EBITDA Margin1.64

Stock Splits

Aarey Drugs & Pharmaceuticals Ltd.'s most recent stock split took place on June 25, 2012 with a 5:6 split ratio.

Last Split Date6/25/2012
Split Ratio5:6